Posts

Alnylam Cuts Amvuttra Sales Guidance as Second-Line Demand Normalizes, Hitting Stock

on

Teva's Innovation Engine Offsets Generics Slump, Leaving Analyst Shocked by Ajovy Surge

on

AZ, Ionis Shares Tumble on ATTR‑CM Trial Flop, But Analyst Flags Over‑Reaction Explained

on

Top performers of the second quarter 2026: chips, AI, and Asia lead gains

on

uniQure Announces Pricing of Upsized $225 Million Public Offering: Details and Highlights

on

The Oral GLP-1 Tracker: Novo’s Wegovy keeps gaining ground in obesity market

on

Oral GLP‑1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

on

SKIA HEAD Gains FDA Clearance for AR Surgical Guidance

on

Roche's Tecentriq, Pfizer/Astellas' Padcev and Merck's Keytruda in Bladder Cancer Battle: Recent Updates

on

Angelini Fortifies Neurology Portfolio with $4.1B Buyout of Catalyst

on

How To Shine As Biotech Comes Back From the Brink: Upcoming Virtual Event

on

Strengthening Payer Engagement with Real-World Evidence: Recent Developments

on

Recent Advances in Wet AMD Treatments and Market Insights

on

Recent Biotech and Pharma News - March 2026

on

The Oncology Market: Outlook for 2026

on

How GLP-1 Weight Loss Compounders Reshaped the Drug Industry

on

Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front

on

KOL Bulletin: ONS-5010's Bigger Opportunity May Lie Outside the US After FDA's Third CRL, KOL Says

on

Orphan Drug Trends: A Data-Driven Analysis

on

The Endpoints 100: Biotech CEOs are feeling more upbeat about the road ahead

on